Patents Assigned to MedImmune Limited
  • Anti-VEGF-A antibodies and uses thereof
    Patent number: 10919958
    Abstract: The present invention relates to antibodies having activity against a vascular endothelial growth factor (VEGF), and methods of making and using such antibodies.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: February 16, 2021
    Assignee: MEDIMMUNE LIMITED
    Inventors: Ching Ching Leow, Nazzareno Dimasi, Karen Coffman, Ping Tsui, Changshou Gao, Mario A. Cepeda, Adrian Schwartz Mittelman
  • ANTI-VEGF-A AND ANTI-ANG2 ANTIBODIES AND USES THEREOF
    Publication number: 20210040194
    Abstract: The present invention relates to bispecific antibodies having activity against a vascular endothelial growth factor (VEGF) and an angiopoietin (ANG), and methods of making and using such bispecific antibodies.
    Type: Application
    Filed: October 14, 2020
    Publication date: February 11, 2021
    Applicant: MEDIMMUNE LIMITED
    Inventors: Ching Ching Leow, Nazzareno Dimasi, Karen Coffman, Ryan Fleming, Ping Tsui, Changshou Gao, Mario A. Cepeda, Adrian Schwartz Mittelman
  • Antibodies to alpha-synuclein and uses thereof
    Patent number: 10889639
    Abstract: The invention provides antibodies that specifically bind human ?-synuclein with a high affinity and reduces ?-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating ?-synuclein antibodies, and methods of using ?-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: January 12, 2021
    Assignee: MedImmune Limited
    Inventors: Darren Schofield, Michael Perkinton, Lorraine Irving, George Thom
  • Synthetic oligosaccharide subunits of the Psl exopolysaccharide of pseudomonas aeruginosa and uses thereof
    Patent number: 10870710
    Abstract: This disclosure relates to synthetic oligosaccharide subunits of the Pseudomonas exosaccharide Psi and uses thereof, e.g., for epitope mapping of anti-Psl antibodies, for identification of anti-Psl antibodies, and for use as vaccines. In one aspect a synthetic oligosaccharide subunit of a Pseudomonas aeruginosa Psl oligosaccharide is provided, comprising the trisaccharide of formula I.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: December 22, 2020
    Assignees: MedImmune Limited, University of Georgia Research Foundation, Inc.
    Inventors: Antonio DiGiandomenico, Qun Wang, Charles K. Stover, Geert-Jan Boons, Kai-For Mo, Huiqing Li
  • Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
    Patent number: 10864269
    Abstract: The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MEDI9447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: December 15, 2020
    Assignee: MedImmune Limited
    Inventors: Kris Sachsenmeier, Erin Sult, Carl Hay, Edmund Poon
  • Anti-Psl binding molecules and uses thereof
    Patent number: 10844114
    Abstract: This disclosure relates to an anti-Pseudomonas Psl binding molecule and uses thereof, in particular in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: November 24, 2020
    Assignee: MedImmune Limited
    Inventors: Antonio DiGiandomenico, Paul G. Warrener, Charles K. Stover, Bret Sellman, Sandrine Guillard, Ralph Minter, Steven Rust, Mladen Tomich
  • Anti-VEGF-A and anti-ANG2 antibodies and uses thereof
    Patent number: 10836819
    Abstract: The present invention relates to bispecific antibodies having activity against a vascular endothelial growth factor (VEGF) and an angiopoietin (ANG), and methods of making and using such bispecific antibodies.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: November 17, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Ching Ching Leow, Nazzareno Dimasi, Karen Coffman, Ryan Fleming, Ping Tsui, Changshou Gao, Mario A. Cepeda, Adrian Schwartz Mittelman
  • Anti-PAR2 antibodies and uses thereof
    Patent number: 10836822
    Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of binding PAR2. In some embodiments, the anti-PAR2 antibodies or antigen-binding fragments thereof bind PAR2 in a pH-dependent manner. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: November 17, 2020
    Assignee: MedImmune Limited
    Inventors: Claire Dobson, Richard Williams, Ian Gurrell, Sadhana Podichetty, David Fairman, Peter Thornton, Philip Newton
  • Phage display library, members thereof and uses of the same
    Patent number: 10829540
    Abstract: The present invention relates to a library (in particular a phage display library) from which an improved human antibody having greater specificity and potency for its target may be generated; and to methods of generating such a human antibody. In particular, the invention relates to a human antibodies against challenging targets obtainable from such a library and which have HCDR3s of at least 18 amino acids in length.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: November 10, 2020
    Assignee: Medimmune Limited
    Inventors: Tristan Vaughan, David Lowe, Stacey Chin, Benjamin David Grimshaw, James Button
  • Anti-B7-H1 antibodies for treating tumors
    Patent number: 10829557
    Abstract: Provided herein are methods of treating B7-H1-expressing tumors comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: November 10, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Rajesh Narwal, David Fairman, Paul Robbins, Meina Liang, Amy Schneider, Carlos Chavez, Carina Herl, Min Pak, Hong Lu, Marlon Rebelatto, Keith Steele, Anmarie Boutrin, Li Shi, Shengyan Hong, Brandon Higgs, Lorin Roskos
  • Anti-PrP antibodies and uses thereof
    Patent number: 10808034
    Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of binding PrPC. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: October 20, 2020
    Assignee: MedImmune Limited
    Inventors: Matthew Gardener, Jayne Hammersley, Maria Groves, Gareth Rees, Sadhana Podichetty, Andrew Billinton
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 10799596
    Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: October 13, 2020
    Assignees: ADC THERAPEUTICS S.A., MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Pyrrolobenzodiazepine conjugates
    Patent number: 10799595
    Abstract: A compound of formula (I): (I) and its conjugates.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: October 13, 2020
    Assignee: MedImmune Limited
    Inventors: Philip Wilson Howard, Stephen John Gregson
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 10780096
    Abstract: The present disclosure relates to the use of antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine (PBD) dimers and anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: September 22, 2020
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITED
    Inventors: Patricius Henrikus Cornelis Van Berkel, Philip Wilson Howard, John Hartley
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 10780181
    Abstract: Conjugates of an antibody that binds to CD19 with PBD dimers.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: September 22, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Anti-RSV monoclonal antibody formulation
    Patent number: 10774133
    Abstract: The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: September 15, 2020
    Assignee: MedImmune Limited
    Inventors: Brian Lobo, Deborah Goldberg
  • FORMULATIONS OF MONOCLONAL ANTIBODIES
    Publication number: 20200283516
    Abstract: The present invention provides a formulation comprising: (i) a monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater (e.g. about 50 mg/ml to about 200 mg/ml) and the ionic excipient is present at a concentration of about 50 to about 150 mM and the formulation has a pH of 5.5 to 6.5.
    Type: Application
    Filed: February 28, 2018
    Publication date: September 10, 2020
    Applicant: MEDIMMUNE LIMITED
    Inventors: Brian LOBO, Deborah Sweet GOLDBERG, Monika Sood SHARMA, Ambarish Umakant SHAH
  • Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
    Patent number: 10751346
    Abstract: Conjugates of an antibody that binds to PSMA with PBD dimers.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: August 25, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
    Patent number: 10736903
    Abstract: Conjugates of an antibody that binds to PSMA with PBD dimers.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: August 11, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • RSV-specific binding molecules and means for producing them
    Patent number: 10730931
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: August 4, 2020
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda